Patrick Nef

Financière Arbevel SA is an independent asset management firm headquartered in Paris, France. The firm was founded in 1997 and manages small and medium-sized French and European funds. Financière Arbevel is a socially responsible investor and signatory to the UN Principles for Responsible Investment (UNPRI) which integrates environmental, social, and governance considerations into their investment process.

France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin.

Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden.

CYTOO SA operates as a contract research organization which develops physiological cell-based assays. It focuses on developing, manufacturing, and commercializing new technologies for cell analysis for life sciences research community. The company has offices in Bethesda and Grenoble. The company was founded by François Chatelain, Alexandra Fuchs and Jacques Lewiner in 2008 and is headquartered in Grenoble, France.

Part of Société Générale SA, Camilla SNC is an investment holding French company. The company is based in Puteaux, France and was founded in 2005.

Indicia Production SASU provides biotechnology research and development services. It manufactures ready-to-use microbiological media for the food and pharmaceutical industry. The company was founded in 1993 and is headquartered in Saint-Genis-l'Argentiere, France.

Based in Lyon within the Center of excellence in Infectious Diseases, Platine Pharma Services is an essential source of immune information for scientists and clinicians. From protocol support to regulatory reports, the company designs, performs and interprets complex molecular and cellular assays. Platine actively supports the development of in-vitro diagnostic, cosmetic and therapeutic product candidates, highlighting key markers and features in both normal and pathological conditions, and guiding decisions at each development stage. Using state-of-the-art technologies such as multi-parametric flow cytometry, Singulex, Luminex, Mesoscale Discovery, ELISpot or ELISA, Platine Pharma Services offers a fit-for-purpose approach to its customers and partners.

Clevexel Pharma SAS manufactures as well as distributes pharmaceutical products. It engages in biotechnological research. The company was founded by Christian Bloy, Xiuping Wang-Zhang and Laurent Benel in 2012 and is headquartered in Paris, France.

BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon.

MabDesign Association is a French biotherapy industry association that aims to structure the biopharmaceutical industry from its R&D phases to biomanufacturing and marketing. The private company is based in Lyon, France and was founded in 2014. The association offers services to help companies strengthen their competitiveness and implement a solid intellectual property strategy. MabDesign's board of directors is composed of a pharmaceutical industry college and a competitiveness cluster college. The CEO is Nicolas Groux.

Keranova SA designs and develops surgical equipment for various ophthalmologic indications that involve the anterior segment of the eye. The company was founded by Fabrizio Romano on September 4, 2015 and is headquartered in Saint-Etienne, France.

Indicia Participations functions as an investment holding French company. The private company is based in Saint-Genis-l'Argentière, France.

SCI CALIFORNIE is a French company that leases real estate properties.

Scipio Bioscience SAS operates as a biotechnology company. It provides a novel sample preparation solution for single-cell studies, in the form of benchtop kits, for use in sequencing applications in clinical and basic research, in particular transcriptomics. The company was founded by Pierre Walrafen and Stuart Edelstein on August 2, 2017 and is headquartered in Paris, France.

NG Biotech SAS is a French family-owned company founded in 2012 by a pioneer of the rapid test industry. The private company is based in Guipry-Messac, France. The company designs and manufactures innovative in vitro diagnostic tools suitable for decision making in medical emergencies, in the laboratory, and at the bedside. NG Biotech's innovation capabilities are powered by an expert R&D team backed by public-private scientific collaborations. The company proposes rapid tests in three main areas\: antimicrobial resistance, infectious disease (including COVID-19 tests), and women's health (blood pregnancy self-tests). NG Biotech's products are available in more than 70 countries, including the USA. The CEO is Milovan Stankov-Pugès.

Mexbrain SAS is a French company that specializes in increasing the efficiency of treatment by combining the best of both worlds. The company is based in Fontaines-Saint-Martin, France. Mexbrain invites interested parties to contact them for any questions or investment opportunities. However, Thomas Brichart has been the CEO since incorporation.

Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison.